NVS Novartis AG

-0.35  -0%
Previous Close 93.42
Open 93.57
Price To Book 2.74
Market Cap 215100724897
Shares 2,311,171,429
Volume 814,494
Short Ratio 1.1
Av. Daily Volume 2,006,392

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.
Cosentyx (secukinumab) - SURPASS
Ankylosing spondylitis (AS)
Approval announced April 30, 2018.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Melanoma with BRAF V600E or V600K mutations
Phase 3 rPFS data due in 2020.
Metastatic castration-resistant prostate cancer (mCRPC)
Approval announced May 11, 2018.
Multiple Sclerosis (MS)
Phase 1 initiation of dosing announced January 16, 2018.
Spinal muscular atrophy (SMA) Type 2
FDA Approval announced June 22, 2017.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Approval announced May 1, 2018.
Kymriah (CTL019 )- JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3 updated data at ASCO June 4, 2017.
Ribociclib + Letrozole - MONALEESA-2
Breast cancer
CRL issued May 2, 2018.
Biosimilar rituximab
Various blood cancers, rheumatoid arthritis.
Priority review granted February 22, 2017. Approval announced May 26, 2017.
First-line use in patients with ALK+ metastatic NSCLC
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Regulatory filing due 2019.
Sickle Cell Disease Pain Crises (SCPC)
CRL announced October 18, 2018.
ACZ885 (canakinumab)
CV risk reduction
Phase 3 data released March 22, 2017 - primary endpoints not met.
Acute heart failure
Phase 3 data released June 20, 2017 - primary and key secondary endpoints met. Additional data presented at ARVO conference April 30, 2018.
RTH258 (brolucizumab)
Neovascular AMD
Phase 3 trial to be completed 3Q 2019.
Phase 3 data due 2H 2019.
QAW039 (fevipiprant)
Phase 3 trial met primary endpoint - November 8, 2017.
Breast cancer - (pre-menopausal)
Phase 3 data due 2H 2019.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 data presented at ASCO 2018 - PFS 20.5 months v 12.8 months
Kisqali plus fulvestrant: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 data due 3Q 2019.
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 trial completion due 2H 2020.
Entresto - PARADISE
AMI (acute myocardial infarction)
Approval announced early - August 30, 2017.
Kymriah (CTL019)
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Phase 3 trial to be completed 2Q 2019.
AIN457 (Cosentyx)
Psoriatic arthritis
Approval announced May 17, 2018.
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Priority review granted November 1, 2016. Approval announced March 13, 2017.
HR+/HER2- advanced breast cancer
FDA approval announced October 31, 2018.
Rheumatoid Arthritis
Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).
Inoperable progressive midgut NETs
PDUFA date under priority review May 2019. Exact date not released.
Spinal muscular atrophy (SMA) Type 1
PDUFA date under priority review extended by three months to May 24, 2019.
Graft versus host disease
Pivotal trial initiated 2Q 2018 (Europe). To be completed in 2020.
Spinal muscular atrophy (SMA) Type 1
Phase 2 interim analysis 1H 2018.
Non-alcoholic steatohepatitis (NASH)
Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients.
Non-small cell lung cancer
Program discontinued - noted July 18, 2018.
Phase 3 trial met primary endpoint - August 23, 2018. PFS 11 months v 5.7 months for fulvestrant alone.
BYL719 + fulvestrant
HR + Metastatic breast cancer (MBC)
FDA approval announced February 8, 2018.
sNDA approval announced November 16, 2018.
Promacta (eltrombopag)
Severe aplastic anemia (SAA)
PDUFA date under priority review set for March 2019. Exact date not noted.
Secondary progressive multiple sclerosis
Phase 3 data due 2H 2019.
BRAFV600 mutant metastatic melanoma
Phase 3 data noted 46% reduction in serious clinical outcomes endpoint.
Entresto - PIONEER
Heart failure
Regulatory filing due 1H 2019.
Sickle cell disease
Phase 3 first data due 2Q 2019.
Entresto - PARALLEL-HF
Heart failure
Phase 3 readout due 2019.
Cosentyx (secukinumab) - PREVENT
Non-radiographic axial spondyloarthritis
FDA Approval announced February 13, 2019.

Latest News

  1. Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more
  2. Alcon Inc. -- Moody's assigns Baa2 issuer rating to Alcon; stable outlook
  3. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
  4. Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
  5. Biogen Stock Crashes on Termination of Alzheimer's Studies
  6. Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo
  7. Novartis says listing of Alcon eye care business expected on April 9
  8. Is Biogen a Bad-News Buy Now?
  9. Cooper Companies' (COO) CooperVision Gains Momentum Globally
  10. Major biotech landlord plants flag in East Bay with acquisition of Novartis site
  11. Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
  12. Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
  13. Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs
  14. 3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?
  15. Tilray Inc (TLRY) Q4 2018 Earnings Conference Call Transcript
  16. Alnylam's (ALNY) Impressive Pipeline Drives Share Price
  17. Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
  18. Roche Gets Approval for Label Expansion of MabThera in Europe
  19. The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA